PTEN mutations, which occur in approximately 4.5% of cases of ccRCC, remove the inhibitory effect on the PI3K/AKT pathway, leading to increased proliferation and migration of tumor cells (31, 148). This evidence concerns the gene PTEN and neoplasm.